{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T03:33:50Z","timestamp":1790048030672,"version":"4.0.1"},"reference-count":90,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"am","delay-in-days":354,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-19-10689"],"award-info":[{"award-number":["W81XWH-19-10689"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-19-10690"],"award-info":[{"award-number":["W81XWH-19-10690"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["RSG-17-022-01-CPPB"],"award-info":[{"award-number":["RSG-17-022-01-CPPB"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["K08 CA248473"],"award-info":[{"award-number":["K08 CA248473"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 DK 56338"],"award-info":[{"award-number":["P30 DK 56338"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA186566"],"award-info":[{"award-number":["R01CA186566"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U01CA230997"],"award-info":[{"award-number":["U01CA230997"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP150587"],"award-info":[{"award-number":["RP150587"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.cgh.2023.05.024","type":"journal-article","created":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T13:32:38Z","timestamp":1686403958000},"page":"91-101.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Hepatocellular Carcinoma Incidence Threshold for Surveillance in Virologically Cured Hepatitis C Individuals"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8741-4430","authenticated-orcid":false,"given":"Jagpreet","family":"Chhatwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Hajjar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter P.","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gizem","family":"Nemutlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeti","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Linton B.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fasiha","family":"Kanwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2023.05.024_bib1","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","article-title":"Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents","volume":"153","author":"Kanwal","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.05.024_bib2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/hep.30823","article-title":"Long-term risk of hepatocellular carcinoma in HCV patients treated with direct acting antiviral agents","volume":"71","author":"Kanwal","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.05.024_bib3","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1053\/j.gastro.2017.08.052","article-title":"Risk for hepatocellular carcinoma after hepatitis C virus antiviral therapy with direct-acting antivirals: case closed?","volume":"153","author":"Maan","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.05.024_bib4","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/hep.28571","article-title":"Hepatitis C disease burden in the United States in the era of oral direct-acting antivirals","volume":"64","author":"Chhatwal","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.05.024_bib5","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.21173","article-title":"Assessment of incidence of and surveillance burden for hepatocellular carcinoma among patients with hepatitis C in the era of direct-acting antiviral agents","volume":"3","author":"Chen","year":"2020","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.cgh.2023.05.024_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001624","article-title":"Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis","volume":"11","author":"Singal","year":"2014","journal-title":"PLoS Med"},{"key":"10.1016\/j.cgh.2023.05.024_bib7","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/nutrit\/nuw063","article-title":"Lipid-modifying effects of krill oil in humans: systematic review and meta-analysis of randomized controlled trials","volume":"75","author":"Ursoniu","year":"2017","journal-title":"Nutr Rev"},{"key":"10.1016\/j.cgh.2023.05.024_bib8","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.05.024_bib9","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.drugpo.2019.06.003","article-title":"What is killing people with hepatitis C virus infection? analysis of a population-based cohort in Canada","volume":"72","author":"Krajden","year":"2019","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.cgh.2023.05.024_bib10","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","article-title":"Asia\u2013Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update","volume":"11","author":"Omata","year":"2017","journal-title":"Hepatology International"},{"key":"10.1016\/j.cgh.2023.05.024_bib11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/hep.32430","article-title":"Is it time to refine HCC surveillance strategies in HCV cured patients?","volume":"76","author":"D\u2019Ambrosio","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.05.024_bib12","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","article-title":"Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study","volume":"393","author":"Carrat","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2023.05.024_bib13","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","article-title":"Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents","volume":"153","author":"Kanwal","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.05.024_bib14","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1053\/j.gastro.2018.07.015","article-title":"Incidence of hepatocellular carcinoma after direct antiviral therapy for HCV in patients with cirrhosis included in surveillance programs","volume":"155","author":"Nahon","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.05.024_bib15","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/jvh.13276","article-title":"Incidence of HCC in chronic hepatitis C patients with advanced hepatic fibrosis who achieved SVR following DAAs: a prospective study","volume":"27","author":"Shiha","year":"2020","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.cgh.2023.05.024_bib16","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1002\/hep.29707","article-title":"The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: an ERCHIVES study","volume":"67","author":"Li","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.05.024_bib17","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1053\/j.gastro.2018.04.008","article-title":"Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents","volume":"155","author":"Calvaruso","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.05.024_bib18","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jhep.2022.01.027","article-title":"Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication","volume":"77","author":"Mueller","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.05.024_bib19","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/hep.29487","article-title":"Imaging for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis","volume":"67","author":"Roberts","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.05.024_bib20","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1053\/j.gastro.2018.01.064","article-title":"Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis","volume":"154","author":"Tzartzeva","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.05.024_bib21","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/j.1600-6143.2010.03021.x","article-title":"Trends in organ donation and transplantation in the United States, 1999-2008","volume":"10","author":"Wolfe","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cgh.2023.05.024_bib22","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/jhep.2003.50047","article-title":"Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival","volume":"37","author":"Llovet","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.05.024_bib23","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/cncr.20426","article-title":"Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey","volume":"101","author":"Ikai","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.cgh.2023.05.024_bib24","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","article-title":"EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma","volume":"56","author":"Llovet","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.05.024_bib25","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/hep.21933","article-title":"Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice?","volume":"47","author":"Livraghi","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.05.024_bib26","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1148\/radiol.2343040350","article-title":"Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation","volume":"234","author":"Lencioni","year":"2005","journal-title":"Radiology"},{"key":"10.1016\/j.cgh.2023.05.024_bib27","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.3748\/wjg.v22.i10.2993","article-title":"Ten-year survival of hepatocellular carcinoma patients undergoing radiofrequency ablation as a first-line treatment","volume":"22","author":"Yang","year":"2016","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cgh.2023.05.024_bib28","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.hpb.2016.06.010","article-title":"Longterm survival outcomes of patients undergoing treatment with radiofrequency ablation for hepatocellular carcinoma and metastatic colorectal cancer liver tumors","volume":"18","author":"Sucandy","year":"2016","journal-title":"HPB"},{"key":"10.1016\/j.cgh.2023.05.024_bib29","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/2050640616659024","article-title":"Prognostic factors of hepatocellular carcinoma survival after radiofrequency ablation: a US population-based study","volume":"5","author":"El-Fattah","year":"2017","journal-title":"United European Gastroenterology Journal"},{"key":"10.1016\/j.cgh.2023.05.024_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/ctg.2017.26","article-title":"Cost-effectiveness of risk score\u2013stratified hepatocellular carcinoma screening in patients with cirrhosis","volume":"8","author":"Goossens","year":"2017","journal-title":"Clinical and Translational Gastroenterology"},{"key":"10.1016\/j.cgh.2023.05.024_bib31","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jhep.2008.07.029","article-title":"The burden of illness associated with hepatocellular carcinoma in the United States","volume":"50","author":"Lang","year":"2009","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.05.024_bib32","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1053\/jlts.2002.31345","article-title":"Assessing health-related quality of life pre- and post-liver transplantation: a prospective multicenter study","volume":"8","author":"Ratcliffe","year":"2002","journal-title":"Liver Transpl"},{"key":"10.1016\/j.cgh.2023.05.024_bib33","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1524-4733.2008.00448.x","article-title":"Mapping the English and Chinese versions of the functional assessment of cancer therapy-general to the EQ-5D utility index","volume":"12","author":"Cheung","year":"2009","journal-title":"Value in Health"},{"key":"10.1016\/j.cgh.2023.05.024_bib34","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/j.suronc.2011.10.005","article-title":"Health-related quality of life in patients with hepatocellular carcinoma after hepatic resection, transcatheter arterial chemoembolization, radiofrequency ablation or no treatment","volume":"21","author":"Toro","year":"2012","journal-title":"Surg Oncol"},{"key":"10.1016\/j.cgh.2023.05.024_bib35","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1001\/jama.1996.03540150055031","article-title":"Recommendations of the Panel on Cost-effectiveness in Health and Medicine","volume":"276","author":"Weinstein","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.cgh.2023.05.024_bib36","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jhep.2009.12.028","article-title":"Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis","volume":"52","author":"Cardoso","year":"2010","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.05.024_bib37","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.05.024_bib38","series-title":"United States life tables, 2017","first-page":"67","author":"Arias","year":"2018"},{"key":"10.1016\/j.cgh.2023.05.024_bib39","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1038\/sj.bjc.6602590","article-title":"Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients","volume":"92","author":"Greten","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cgh.2023.05.024_bib40","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.cgh.2008.08.005","article-title":"Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis","volume":"6","author":"Andersson","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.05.024_bib41","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","article-title":"Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies","volume":"44","author":"D\u2019Amico","year":"2006","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.05.024_bib42","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.cgh.2018.10.031","article-title":"Hepatocellular carcinoma screening is associated with increased survival of patients with cirrhosis","volume":"17","author":"Choi","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.05.024_bib43","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1038\/sj.bjc.6604301","article-title":"Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis","volume":"98","author":"Thompson Coon","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cgh.2023.05.024_bib44","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/hep.26944","article-title":"Hepatocellular carcinoma screening in patients with compensated hepatitis C virus (HCV)-related cirrhosis aware of their HCV status improves survival: a modeling approach","volume":"59","author":"Mourad","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.05.024_bib45","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jval.2013.07.006","article-title":"Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States","volume":"16","author":"Chhatwal","year":"2013","journal-title":"Value in Health"},{"key":"10.1016\/j.cgh.2023.05.024_bib46","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s10620-006-9493-6","article-title":"Liver biopsy: is the pain for real or is it only the fear of it?","volume":"52","author":"Akay","year":"2007","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2023.05.024_bib47","doi-asserted-by":"crossref","DOI":"10.3310\/hta19090","article-title":"Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation","volume":"19","author":"Crossan","year":"2015","journal-title":"Health Technology Assessment"},{"key":"10.1016\/j.cgh.2023.05.024_bib48","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/hep.510270506","article-title":"Cost-effectiveness of\u00a0ultrasound-guided liver biopsy","volume":"27","author":"Pasha","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.05.024_bib49","unstructured":"Centers for Medicare & Medicaid Services,\u00a02021."},{"key":"10.1016\/j.cgh.2023.05.024_bib50","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s10620-016-4044-2","article-title":"Screening for nonalcoholic steatohepatitis in individuals with type 2 diabetes: a cost-effectiveness analysis","volume":"61","author":"Corey","year":"2016","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2023.05.024_bib51","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness: the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2023.05.024_bib53","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1053\/j.gastro.2008.11.023","article-title":"Hepatitis C and hepatocellular carcinoma: grist for the mill","volume":"136","author":"Sherman","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.05.024_bib54","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/j.cgh.2018.12.018","article-title":"Cost effectiveness of hepatocellular carcinoma surveillance after a sustained virologic response to therapy in patients with hepatitis C virus infection and advanced fibrosis","volume":"17","author":"Farhang Zangneh","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.05.024_bib55","article-title":"Fibrosis-stage specific incidence of hepatocellular cancer after hepatitis C cure with direct-acting antivirals: a systematic review & meta-analysis","author":"Kim","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.05.024_bib56","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jhep.2020.10.016","article-title":"HCC surveillance after SVR in patients with F3\/F4 fibrosis","volume":"74","author":"Ioannou","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.05.024_bib57","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","article-title":"Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study","volume":"393","author":"Carrat","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2023.05.024_bib58","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1287\/opre.2017.1706","article-title":"Optimal M-switch surveillance policies for liver cancer in a hepatitis C\u2013infected population","volume":"66","author":"Chen","year":"2018","journal-title":"Oper Res"},{"key":"10.1016\/j.cgh.2023.05.024_bib59","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3350\/cmh.2015.21.3.279","article-title":"Growth rate of early-stage hepatocellular carcinoma in patients with chronic liver disease","volume":"21","author":"An","year":"2015","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.cgh.2023.05.024_bib60","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1002\/hep.31159","article-title":"Hepatocellular carcinoma demonstrates heterogeneous growth patterns in a multicenter cohort of patients with cirrhosis","volume":"72","author":"Rich","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.05.024_bib61","first-page":"401","article-title":"Hepatocellular carcinoma tumour volume doubling time: a systematic review and meta-analysis","volume":"70","author":"Nathani","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2023.05.024_bib62","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1038\/sj.bjc.6602590","article-title":"Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients","volume":"92","author":"Greten","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cgh.2023.05.024_bib63","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.cgh.2008.08.005","article-title":"Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis","volume":"6","author":"Andersson","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.05.024_bib64","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","article-title":"Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies","volume":"44","author":"D\u2019Amico","year":"2006","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.05.024_bib65","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3109\/07357907.2016.1166232","article-title":"Safety, utilization, and cost of image-guided percutaneous liver biopsy among cancer patients","volume":"34","author":"Cui","year":"2016","journal-title":"Cancer Invest"},{"key":"10.1016\/j.cgh.2023.05.024_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2022.01.027","article-title":"Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication","author":"Mueller","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.05.024_bib67","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/j.1600-6143.2010.03021.x","article-title":"Trends in organ donation and transplantation in the United States, 1999-2008","volume":"10","author":"Wolfe","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cgh.2023.05.024_bib68","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/jhep.2003.50047","article-title":"Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival","volume":"37","author":"Llovet","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.05.024_bib69","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/cncr.20426","article-title":"Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey","volume":"101","author":"Ikai","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.cgh.2023.05.024_bib70","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","article-title":"EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma","volume":"56","author":"Llovet","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.05.024_bib71","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/hep.21933","article-title":"Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice?","volume":"47","author":"Livraghi","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.05.024_bib72","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1148\/radiol.2343040350","article-title":"Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation","volume":"234","author":"Lencioni","year":"2005","journal-title":"Radiology"},{"key":"10.1016\/j.cgh.2023.05.024_bib73","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.3748\/wjg.v22.i10.2993","article-title":"Ten-year survival of hepatocellular carcinoma patients undergoing radiofrequency ablation as a first-line treatment","volume":"22","author":"Yang","year":"2016","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cgh.2023.05.024_bib74","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.hpb.2016.06.010","article-title":"Longterm survival outcomes of patients undergoing treatment with radiofrequency ablation for hepatocellular carcinoma and metastatic colorectal cancer liver tumors","volume":"18","author":"Sucandy","year":"2016","journal-title":"HPB"},{"key":"10.1016\/j.cgh.2023.05.024_bib75","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/2050640616659024","article-title":"Prognostic factors of hepatocellular carcinoma survival after radiofrequency ablation: a US population-based study","volume":"5","author":"El-Fattah","year":"2017","journal-title":"United Eur Gastroenterol J"},{"key":"10.1016\/j.cgh.2023.05.024_bib76","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1053\/j.gastro.2018.01.064","article-title":"Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis","volume":"154","author":"Tzartzeva","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.05.024_bib77","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/hep.29487","article-title":"Imaging for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis","volume":"67","author":"Roberts","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.05.024_bib78","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/lt.25398","article-title":"Frequency and outcomes of abnormal imaging in patients with cirrhosis enrolled in a hepatocellular carcinoma surveillance program","volume":"25","author":"Konerman","year":"2019","journal-title":"Liver Transplant"},{"key":"10.1016\/j.cgh.2023.05.024_bib79","doi-asserted-by":"crossref","DOI":"10.1038\/ctg.2017.26","article-title":"Cost-effectiveness of risk score\u2013stratified hepatocellular carcinoma screening in patients with cirrhosis","volume":"8","author":"Goossens","year":"2017","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.cgh.2023.05.024_bib81","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s10620-016-4044-2","article-title":"Screening for nonalcoholic steatohepatitis in individuals with type 2 diabetes: a cost-effectiveness analysis","volume":"61","author":"Corey","year":"2016","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2023.05.024_bib82","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1038\/sj.bjc.6604301","article-title":"Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis","volume":"98","author":"Thompson Coon","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cgh.2023.05.024_bib83","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jhep.2008.07.029","article-title":"The burden of illness associated with hepatocellular carcinoma in the United States","volume":"50","author":"Lang","year":"2009","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.05.024_bib84","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jval.2013.07.006","article-title":"Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States","volume":"16","author":"Chhatwal","year":"2013","journal-title":"Value in Health"},{"key":"10.1016\/j.cgh.2023.05.024_bib85","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s10620-006-9493-6","article-title":"Liver biopsy: is the pain for real or is it only the fear of it?","volume":"52","author":"Akay","year":"2007","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2023.05.024_bib86","doi-asserted-by":"crossref","DOI":"10.3310\/hta19090","article-title":"Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation","volume":"19","author":"Crossan","year":"2015","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.cgh.2023.05.024_bib87","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/hep.510270506","article-title":"Cost-effectiveness of ultrasound-guided liver biopsy","volume":"27","author":"Pasha","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.05.024_bib88","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1053\/jlts.2002.31345","article-title":"Assessing health-related quality of life pre- and post-liver transplantation: a prospective multicenter study","volume":"8","author":"Ratcliffe","year":"2002","journal-title":"Liver Transplant"},{"key":"10.1016\/j.cgh.2023.05.024_bib89","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1524-4733.2008.00448.x","article-title":"Mapping the English and Chinese versions of the functional assessment of cancer therapy-general to the EQ-5D utility index","volume":"12","author":"Cheung","year":"2009","journal-title":"Value in Health"},{"key":"10.1016\/j.cgh.2023.05.024_bib90","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/j.suronc.2011.10.005","article-title":"Health-related quality of life in patients with hepatocellular carcinoma after hepatic resection, transcatheter arterial chemoembolization, radiofrequency ablation or no treatment","volume":"21","author":"Toro","year":"2012","journal-title":"Surg Oncol"},{"key":"10.1016\/j.cgh.2023.05.024_bib91","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1365-2036.2009.04014.x","article-title":"Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis","volume":"30","author":"Singal","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2023.05.024_bib92","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jhep.2005.10.002","article-title":"Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study","volume":"44","author":"El-Serag","year":"2006","journal-title":"J\u00a0Hepatol"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356523004469?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356523004469?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:44:08Z","timestamp":1761543848000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356523004469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":90,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1542356523004469"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2023.05.024","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatocellular Carcinoma Incidence Threshold for Surveillance in Virologically Cured Hepatitis C Individuals","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2023.05.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the AGA Institute","name":"copyright","label":"Copyright"}]}}